Barroetabeña RY, Curbelo PRA, Carvajal OJA, Torres ME

Language: Spanish
References: 7
Page:
PDF size: 101.65 Kb.

ABSTRACT

The pilonidal disease is a very common disorder that affects men between the second and third decades of life. It is a great socio-economic and medical problem to affect the nucleus of working adult population motivating labor loss periods and also by its chronicity and recurrence. Currently they have described several variants of therapeutic management; many extend health care and the use of medical supplies for its evolution and definitive cure with the rise of the economic and social costs for the patient and healthcare providers. With the development advent in the country the use of the Heberprot - P, which is based on the factor of recombinant human growth for the management of the diabetic foot almost exclusive, it has opened a spectrum for the management of other injuries aimed at healing. A patient is presented with recurrence pilonidal fistula treated in a surgical way without primary closure where the Heberprot - P was used with healing purposes that he presented a satisfactory evolution and is presented as an alternative for this disease management.

REFERENCES

1. Goligher J. Seno pilonidal. En: Cirugía del ano, recto y colon. 2da ed. Barcelona: Salvat; 1987.

2. Blasco T, García J, Pallas A, Flors C, Roig JV. Experiencia y resultados en el tratamiento quirúrgico del sinus pilonidal sacrocoxígeo. Cir Española. 1998; 63:282-5.

3. Moles L, Fernández J, Vázquez A, Recio J, De Quintana R, Martin R. Enfermedad pilonidal. Tratamiento por exéresis en bloque con cierre primario. Cir Esp. 2000; 68: 570-2.

4. Al–Jaberi TM. Excision and simple primary closure of chronic pilonidal sinus. Eur J Surg. 2001; 167:133-5.

5. Fernández Montequín J. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wounds J. 2007; 4(4):333-43.

6. Fernández Montequín J, Sancho Soutelo N, Fleitas Pérez E, Santiesteban Bonaechea LL. El Heberprot P como indicación terapeútica en el tratamiento curativo de las úlceras por presión. Rev Esp Invest Quirúrg. 2011; 14(3):143-145.

7. Hernández Riverol MJ, Llanes Barriosil JA, Acosta Lapera DS. Heberprot-P, una terapia eficaz en la prevención de la amputación en el pie diabético. Rev Cubana Angiol Cir [Internet]. 2009 [citado 18 Diciembre 2010]; 10(1): [aprox. 8 p.]. Disponible en: http://www.bvs.sld.cu/revistas/ang/vol10_1_09/ang02109.pdf